Kailera Therapeutics, Inc. (KLRA) Income Statement
KLRA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKLRA revenue and net income
KLRA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KLRA quarterly EPS vs estimates
Kailera Therapeutics beat the analyst EPS estimate in 0 of the last 2 quarters. Next report: November 11, 2026 (estimate $-1.55).
KLRA income statement
| 2025 | |
|---|---|
| Revenue | $0 |
| Research & development | $109.1M |
| Sales, general & admin | $49.2M |
| Total operating expenses | $158.3M |
| Operating income | −$158.3M |
| Interest income | $11.0M |
| Income before taxes | −$149.0M |
| Net income | −$149.0M |
| EBITDA | −$158.0M |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $101.1M | $70.9M | $19.5M | $10.1M |
| Sales, general & admin | $20.3M | $13.8M | $11.1M | $10.3M |
| Total operating expenses | $121.4M | $84.7M | $30.7M | $20.5M |
| Operating income | −$121.4M | −$84.7M | −$30.7M | −$20.5M |
| Interest income | $10.0M | $5.7M | $2.1M | $1.7M |
| Income before taxes | −$111.3M | −$78.9M | −$28.9M | −$18.0M |
| Net income | −$111.3M | −$78.9M | −$28.9M | −$18.0M |
| EBITDA | −$111.2M | −$84.6M | −$30.6M | −$20.4M |
| EPS (diluted) | −$1.09 | −$3.65 | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KLRA's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KLRA financial results
Kailera Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $149.0 million.
See the KLRA stock overview for the latest quote and news, or the KLRA chart for price history and technical indicators.
KLRA income statement FAQ
Does Kailera Therapeutics have revenue?
Kailera Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Kailera Therapeutics profitable?
No. Kailera Therapeutics reported a net loss of $149.0 million in fiscal 2025.
How much does Kailera Therapeutics spend on research and development?
Kailera Therapeutics spent $109.1 million on research and development in fiscal 2025.
When will Kailera Therapeutics report its next earnings?
Kailera Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Kailera Therapeutics's fiscal year end?
Kailera Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.